Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
19 June, 2018 06:54 IST
Lupin receives USFDA approval for pregnancy prevention tablets
Source: IRIS | 14 Jun, 2018, 03.47PM
Comments  |  Post Comment

Pharma major Lupin announced that it has received final approval fonts Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and LevomefolateCalcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Bayer HealthCare Pharmaceutical Inc.'s (Bayer) Beyaz®Tablets.

Lupin's Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg, are the generic equivalent of Bayer's Beyaz® Tablets. It is indicated for use by women to:

> prevent pregnancy;

> treat symptoms of premenstrual dysphoric disorder (PMDD) for women who choose to use an oral contraceptive for contraception;

> treat moderate acne for women at least 14 years old, only if the patient desires an oral contraceptive for birth control; and

> raise folate levels in women who choose to use an oral contraceptive for contraception

Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg had annual sales of approximately U5D 82.2 million in the US (IOWA MATApril 2018).

Shares of the company gained Rs 47.7, or 5.58%, to trade at Rs 902.00. The total volume of shares traded was 391,151 at the BSE (3.30 p.m., Thursday).





Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Sector
Retail NBFCs to face funding challenges due to increased borrowing cost and narrow funding avenues: ICRA - 18-Jun-2018 14:57
For vehicle makers, capex to rise over 30% in next 2 fiscals: CRISIL - 18-Jun-2018 14:52
Dr. Reddy's defends right to launch Buprenorphine and Naloxone Sublingual Film - 18-Jun-2018 12:40
AU Small Fin to raise Rs 10 bn from Temasek - 18-Jun-2018 12:32
Lupin, Nichi-Iko in pact for commercialisation of Etanercept in Japan - 18-Jun-2018 11:38
Yes Bank gets SEBI approval for offering custodial services - 18-Jun-2018 10:06
PNC Infratech update on Purvanchal Expressway project bid - 15-Jun-2018 17:03
Fitch affirms at Axis Bank and ICICI Bank's issuer rating at BBB- - 15-Jun-2018 15:36
Dhunseri Petrochem to exit JV in Egypt with Indorama - 15-Jun-2018 15:22
NBCC bags orders worth Rs 4.80 bn in May 2018 - 15-Jun-2018 15:16
BL Kashyap & Sons wins orders worth Rs 6.94 bn - 15-Jun-2018 15:12
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer